As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ...

Gift 5 articles to anyone you choose each month when you subscribe. Christian Behrenbruch, the co-founder and chief executive of $7 billion cancer diagnostic giant Telix Pharmaceuticals, has ...

I am including Pluvicto as the sixth significant growth product for Novartis. Management said on the Q2 earnings call that we should see Pluvicto's growth moderate as the launch is starting to ...

Pluvicto and Lutathera. The University of Missouri Research Reactor, which began producing Lu-177 in 2023, is the only source of this isotope in the U.S. MU announces $5.5 million repairs to ...

2 Months Online Access $1.98 for 60 days 3 Months Online Access $2.97 for 90 days 4 Months Online Access $3.96 for 120 days 5 Months Online Access $4.95 for 150 days 6 Months Online Access $5.94 for ...

Metastatic castration-resistant prostate cancer (mCRPC) and its precursor, metastatic hormone sensitive prostate cancer (mHSPC), are advanced forms of the condition that don’t respond to initial ...

Noa-Lynn van Leuven took the title at the 21st tournament of the PDC Women's Series. This title secures Van Leuven's participation in the PDC World Darts Championship at Alexandra Palace. For Van ...

Treatments for prostate cancer range from watchful waiting (closely monitoring the condition without giving treatment) to surgery. Radiation therapy (radiotherapy) is often used as a first-line ...

NEW YORK – The US Food and Drug Administration on Friday approved Astellas' Vyloy (zolbetuximab-clzb) with chemotherapy as a first-line treatment for patients with locally advanced unresectable or ...

Novartis markets two approved radiopharmaceuticals in neuroendocrine tumor drug Lutathera and Pluvicto for prostate cancer. Meanwhile, radioisotope producer PanTera recently snared 93 million ...

Novartis is currently the radiopharma frontrunner with its FDA-approved prostate cancer therapy Pluvicto, alongside the GEP-NETs treatment Lutathera. In August 2024, Novartis put $2.7 billion on the ...